Pharmacogenomics applied to recombinant human growth hormone responses in children with short stature
- PMID: 33712998
- PMCID: PMC7979669
- DOI: 10.1007/s11154-021-09637-1
Pharmacogenomics applied to recombinant human growth hormone responses in children with short stature
Abstract
We present current knowledge concerning the pharmacogenomics of growth hormone therapy in children with short stature. We consider the evidence now emerging for the polygenic nature of response to recombinant human growth hormone (r-hGH). These data are related predominantly to the use of transcriptomic data for prediction. The impact of the complex interactions of developmental phenotype over childhood on response to r-hGH are discussed. Finally, the issues that need to be addressed in order to develop a clinical test are described.
Keywords: Growth hormone; Interactome; Pharmacogenomics; Transcriptomics.
Conflict of interest statement
AS and PM have received speaker honoraria from Merck KGaA, Darmstadt, Germany. PC has received research investigator support and speaker honoraria from Merck KGaA, Darmstadt, Germany.
Figures

Similar articles
-
Growth hormone receptor exon 3 isoforms and their implication in growth disorders and treatment.Horm Res. 2009 Apr;71 Suppl 2:55-63. doi: 10.1159/000192438. Epub 2009 Apr 29. Horm Res. 2009. PMID: 19407498 Review.
-
Pharmacogenomics related to growth disorders.Horm Res Paediatr. 2013;80(6):477-90. doi: 10.1159/000355658. Epub 2013 Nov 27. Horm Res Paediatr. 2013. PMID: 24296333 Review.
-
Clinical diagnoses of children with extremely short stature and their response to growth hormone.J Pediatr. 1993 May;122(5 Pt 1):687-92. doi: 10.1016/s0022-3476(06)80005-3. J Pediatr. 1993. PMID: 8496743
-
Investigating the Impact of the TUITEK® Patient Support Programme, Designed to Support Caregivers of Children Prescribed Recombinant Human Growth Hormone Treatment in Taiwan.Front Endocrinol (Lausanne). 2022 May 6;13:897956. doi: 10.3389/fendo.2022.897956. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 35600589 Free PMC article.
-
Six-month, prospective, longitudinal, open-label caffeine and dextromethorphan phenotyping study in children with growth hormone deficiency receiving recombinant human growth hormone replacement.Clin Ther. 2008 Sep;30(9):1687-99. doi: 10.1016/j.clinthera.2008.09.012. Clin Ther. 2008. PMID: 18840375
Cited by
-
Short and Long-Term Effects of Growth Hormone in Children and Adolescents With GH Deficiency.Front Endocrinol (Lausanne). 2021 Sep 1;12:720419. doi: 10.3389/fendo.2021.720419. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 34539573 Free PMC article. Review.
-
Use of 'omics for endometrial timing: the cycle moves on.Hum Reprod. 2022 Apr 1;37(4):644-650. doi: 10.1093/humrep/deac022. Hum Reprod. 2022. PMID: 35147196 Free PMC article.
-
Gene Expression Signatures Predict First-Year Response to Somapacitan Treatment in Children With Growth Hormone Deficiency.J Clin Endocrinol Metab. 2024 Apr 19;109(5):1214-1221. doi: 10.1210/clinem/dgad717. J Clin Endocrinol Metab. 2024. PMID: 38066644 Free PMC article. Clinical Trial.
References
-
- Barstow C, Rerucha C. Evaluation of Short and Tall Stature in Children. Am Fam Physician. 2015;92:43–50. - PubMed
-
- Grimberg A, et al. Guidelines for Growth Hormone and Insulin-Like Growth Factor-I Treatment in Children and Adolescents: Growth Hormone Deficiency, Idiopathic Short Stature, and Primary Insulin-Like Growth Factor-I Deficiency. Horm Res Paediatr. 2016;86:361–397. doi: 10.1159/000452150. - DOI - PubMed
-
- National Institute for Health and Care Excellence: Clinical Guidelines, Human growth hormone (somatropin) for the treatment of growth failure in children. 2010.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources